Boothbay Fund Management’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-53,478
| Closed | -$81.8K | – | 1222 |
|
|
2025
Q1 | $81.8K | Sell |
53,478
-59,006
| -52% | -$90.3K | ﹤0.01% | 1074 |
|
|
2024
Q4 | $279K | Buy |
+112,484
| New | +$279K | 0.01% | 939 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 1449 |
|
|
2023
Q3 | – | Sell |
-40,973
| Closed | -$425K | – | 1487 |
|
|
2023
Q2 | $425K | Sell |
40,973
-20,470
| -33% | -$212K | 0.01% | 990 |
|
|
2023
Q1 | $497K | Buy |
+61,443
| New | +$497K | 0.01% | 1052 |
|
|
2021
Q3 | – | Sell |
-19,174
| Closed | -$337K | – | 1615 |
|
|
2021
Q2 | $337K | Sell |
19,174
-1,807
| -9% | -$31.8K | 0.01% | 1060 |
|
|
2021
Q1 | $529K | Sell |
20,981
-30,480
| -59% | -$769K | 0.02% | 743 |
|
|
2020
Q4 | $333K | Buy |
+51,461
| New | +$333K | 0.01% | 765 |
|
|
2019
Q4 | – | Sell |
-11,700
| Closed | -$13K | – | 725 |
|
|
2019
Q3 | $13K | Buy |
+11,700
| New | +$13K | ﹤0.01% | 650 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 643 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 603 |
|
|
2017
Q4 | – | Sell |
-20,711
| Closed | -$535K | – | 617 |
|
|
2017
Q3 | $535K | Buy |
20,711
+7,791
| +60% | +$201K | 0.09% | 193 |
|
|
2017
Q2 | $350K | Sell |
12,920
-4,325
| -25% | -$117K | 0.07% | 294 |
|
|
2017
Q1 | $514K | Buy |
17,245
+7,532
| +78% | +$224K | 0.1% | 201 |
|
|
2016
Q4 | $264 | Buy |
+9,713
| New | +$264 | 0.06% | 395 |
|